ImmusanT Initiates Phase 2 Enrollment for its Lead Therapeutic Vaccine Candidate in Patients With Celiac Disease in Australia and New Zealand
October 30, 2018 09:00 ET
|
ImmusanT, Inc.
Nexvax2® Currently the Only Disease-Modifying Therapeutic in Clinical Development for Patients with Celiac Disease CAMBRIDGE, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a...